Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Wafik El-Deiry

Email
Center AffiliationsMolecular Therapeutics

Publications (68) (print view)

no pagination
Alpaugh RK, Zhou LL, Dicker DT, Matthew E, El-Deiry WS. Circulating tumor cells: Silent predictors of metastasis. F1000Research. 2017 Jan;6.
Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 Apr 20;35(12):1341-67.
Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017 Jun 20;8(25):39945-62.   PMCID: PMC5522275
El-Deiry WS, Taylor B, Neal JW. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. American Society of Clinical Oncology educational book American Society of Clinical Oncology Meeting. 2017 Jan;37:e8-e15.
Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget. 2017 Sep;8(40):66747-57.   PMCID: PMC5620133
Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch repair deficient metastatic colon cancer and urothelial cancer: a case report of sequential immune checkpoint therapy. Cancer Biol Ther. 2017 Jul 20;:1-4.
Gokare P, El-Deiry WS. The tuberous sclerosis complex gets fatter. Oncotarget. 2017 Jun 27;8(26):41780-1.   PMCID: PMC5522022
Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS. P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Sci Rep. 2017 Aug 29;7(1):9711.   PMCID: PMC5575263
Gokare P, Lulla AR, El-Deiry WS. MMR-deficiency and BRCA2/EGFR/NTRK mutations. Aging. 2017 Aug 03;9(8):1849-50.
Hernandez-Borrero LJ, Zhang S, Lulla A, Dicker DT, El-Deiry WS. CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA. Cell cycle (Georgetown, Tex). 2017 Jul 27;:0.
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerod A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF, Taschner PE, Hainaut P, Soussi T. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res. 2017 Mar 15;77(6):1250-60.
Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol Ther. 2017 Sep 08;:1-11.
Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology and Therapy. 2017 Jan;:1-11.
Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Oct;8(47):81776-93.
Lulla AR, Slifker MJ, Zhou Y, Lev A, Einarson MB, Dicker DT, El-Deiry WS. miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell cycle arrest in colon cancer cells. Cancer Res. 2017 Oct 23;.
Meyer JE, Finnberg NK, Chen L, Cvetkovic D, Wang B, Zhou L, Dong Y, Hallman MA, Ma CC, El-Deiry WS. Tissue TGF-beta expression following conventional radiotherapy and pulsed low-dose-rate radiation. Cell cycle (Georgetown, Tex). 2017 Jun 18;16(12):1171-4.   PMCID: PMC5499842
Mirkin KA, Hollenbeak CS, Mohamed A, Jia Y, El-Deiry WS, Messaris E. Impact of perineural invasion on survival in node negative colon cancer. Cancer Biol Ther. 2017 May 05;:1-6.
Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CL, Van den Heuvel AP, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Jan;12(8):e0180541.   PMCID: PMC5540272
Ralff MD, Kline CL, Kucukkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 demonstrates anti-tumor effects in both triple negative and non-triple negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther. 2017 Jul;16(7):1290-8.   PMCID: PMC5564301
Ralff MD, Lulla AR, Wagner J, El-Deiry WS. ONC201: A new treatment option being tested clinically for recurrent glioblastoma. Translational Cancer Research. 2017 Jan;6:S1239-S1243.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Wafik El-Deiry Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Thursday, November 02, 2017